Entropy Technologies LP Purchases Shares of 2,401 Boston Scientific Co. (NYSE:BSX)

Entropy Technologies LP bought a new position in Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,401 shares of the medical equipment provider's stock, valued at approximately $214,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Values First Advisors Inc. acquired a new stake in Boston Scientific during the third quarter valued at $28,000. Dunhill Financial LLC raised its stake in Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 152 shares during the period. Global Wealth Strategies & Associates raised its stake in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 250 shares during the period. West Oak Capital LLC purchased a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $29,000. Finally, E Fund Management Hong Kong Co. Ltd. purchased a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $30,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares in the company, valued at approximately $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 87,326 shares of company stock valued at $8,673,948. 0.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BSX. Stifel Nicolaus lifted their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a report on Thursday, February 6th. Royal Bank of Canada upped their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. StockNews.com upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, January 29th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research report on Friday, January 10th. Finally, Morgan Stanley upped their price objective on shares of Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and an average price target of $107.39.

Boston Scientific Price Performance

BSX stock traded down $0.98 during trading on Tuesday, hitting $105.13. The company had a trading volume of 2,346,733 shares, compared to its average volume of 5,965,439. Boston Scientific Co. has a fifty-two week low of $65.33 and a fifty-two week high of $107.17. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $154.95 billion, a price-to-earnings ratio of 84.11, a P/E/G ratio of 2.79 and a beta of 0.80. The business has a 50 day moving average of $96.79 and a 200 day moving average of $88.61.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, research analysts predict that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.